NPS PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20150153329 | ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 06-04-2015 |
20140256632 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 09-11-2014 |
20140248641 | CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. | 09-04-2014 |
20140024065 | EX VIVO METHOD FOR DETERMINING POTENTIAL GLP-2 RECEPTOR MODULATORS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-23-2014 |
20140018549 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias, wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 01-16-2014 |
20130203673 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 08-08-2013 |
20130190407 | CALCIUM RECEPTOR-ACTIVE MOLECULES - The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca | 07-25-2013 |
20130157954 | METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION - Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs. | 06-20-2013 |
20130072430 | METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION - Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs. | 03-21-2013 |
20120302596 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY - Described herein are compounds with affinity for the 5-HT | 11-29-2012 |
20120295298 | EX VIVO METHOD FOR DETERMINING POTENTIAL GLP-2 RECEPTOR MODULATORS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 11-22-2012 |
20120148684 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 06-14-2012 |
20120003681 | EX VIVO METHOD FOR DETERMINING POTENTIAL GLP-2 RECEPTOR MODULATIONS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-05-2012 |
20110172152 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 07-14-2011 |
20110130556 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2(1-34) PEPTIDES - The invention provides methods for making peptides from a polypeptide containing at least one copy of the peptide using clostripain to excise the peptide from the polypeptide. The methods enable the use of a single, highly efficient enzymatic cleavage to produce any desired peptide sequence. | 06-02-2011 |
20110092424 | PRODUCTION OF GLUCAGON LIKE PEPTIDE 2 AND ANALOGS - GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In a specific embodiment, [Gly | 04-21-2011 |
20110071081 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 03-24-2011 |
20110009320 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 01-13-2011 |
20100068732 | CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. | 03-18-2010 |
20100003703 | ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-07-2010 |
20090275578 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators - The present invention is directed to compounds of formula I: | 11-05-2009 |
20090176993 | Calcium receptor active compounds - A novel calcium receptor active compound having the formula is provided: | 07-09-2009 |